At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 220 enrolled
Drug / intervention
placebo +1 moredrug
Likely dose
pregabalin 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 17-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Of Pregabalin For The Treatment Of Chronic Central Neuropathic Pain After Spinal Cord Injury
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Dec 5, 2006·Updated Jan 25, 2021
In Brief
A Phase 3 clinical trial evaluating placebo and pregabalin for Neuralgia and Spinal Cord Injuries. Completed, enrolled 220 participants across 67 sites in 10 countries.
Detailed Summary
The purpose of this study is to evaluate if pregabalin relieves nerve pain associated with spinal cord injury compared to placebo (pill that contains no active medicine). This study will also evaluate the safety of pregabalin in this patient population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuralgia, Spinal Cord Injuries
CountriesChile, China, Colombia, Czechia, Hong Kong, India, Japan, Philippines, Russia, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2006
Enrollment StartJan 2007
Primary CompletionFeb 2011
TodayJul 2026
First PostedDec 5, 2006
Enrollment StartJan 1, 2007
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 19.6 years ago
Interventions
placebodrug
Placebo
pregabalindrug
Pregabalin capsules taken twice daily up to 17 weeks (150-600 mg/day)